chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Inappropriate schedule of product administration, Migraine, Myalgia
Clinical narrative: greater than 35 days between doses of the Moderna Covid-19 vaccine; Migraine Headache; Fever; chills; muscle aches; joint aches; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 10-Jun-2021 and was forwarded to Moderna on 10-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (greater than 35 days between doses of the Moderna Covid-19 vaccine), MIGRAINE (Migraine Headache), PYREXIA (Fever), CHILLS (chills) and MYALGIA (muscle aches) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008C21A and 022B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (greater than 35 days between doses of the Moderna Covid-19 vaccine), MIGRAINE (Migraine Headache), PYREXIA (Fever), CHILLS (chills), MYALGIA (muscle aches) and ARTHRALGIA (joint aches). On 09-Jun-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (greater than 35 days between doses of the Moderna Covid-19 vaccine) had resolved. At the time of the report, MIGRAINE (Migraine Headache), PYREXIA (Fever), CHILLS (chills), MYALGIA (muscle aches) and ARTHRALGIA (joint aches) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatments were provided.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: greater than 35 days between doses of the Moderna Covid-19 vaccine; Migraine Headache; Fever; chills; muscle aches; joint aches; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 10-Jun-2021 and was forwarded to Moderna on 10-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (greater than 35 days between doses of the Moderna Covid-19 vaccine), MIGRAINE (Migraine Headache), PYREXIA (Fever), CHILLS (chills) and MYALGIA (muscle aches) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008C21A and 022B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (greater than 35 days between doses of the Moderna Covid-19 vaccine), MIGRAINE (Migraine Headache), PYREXIA (Fever), CHILLS (chills), MYALGIA (muscle aches) and ARTHRALGIA (joint aches). On 09-Jun-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (greater than 35 days between doses of the Moderna Covid-19 vaccine) had resolved. At the time of the report, MIGRAINE (Migraine Headache), PYREXIA (Fever), CHILLS (chills), MYALGIA (muscle aches) and ARTHRALGIA (joint aches) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatments were provided.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2021, the patient experienced PAIN IN EXTREMITY (sore arm). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form. At the time of the report, PAIN IN EXTREMITY (sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Patient missed his 2nd dose, more than 42 days; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Patient missed his 2nd dose, more than 42 days) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Jun-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient missed his 2nd dose, more than 42 days). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Patient missed his 2nd dose, more than 42 days) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Hypoacusis
Clinical narrative: Cant hear very well/hears a muffled voice/ unless the person is standing next to her, cant make out what others are saying/ can feel the vibrations of the noise; dizzy; Headache; This spontaneous case was reported by a consumer and describes the occurrence of HYPOACUSIS (Cant hear very well/hears a muffled voice/ unless the person is standing next to her, cant make out what others are saying/ can feel the vibrations of the noise), DIZZINESS (dizzy) and HEADACHE (Headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 054C21A and 003C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPOACUSIS (Cant hear very well/hears a muffled voice/ unless the person is standing next to her, cant make out what others are saying/ can feel the vibrations of the noise), DIZZINESS (dizzy) and HEADACHE (Headache). At the time of the report, HYPOACUSIS (Cant hear very well/hears a muffled voice/ unless the person is standing next to her, cant make out what others are saying/ can feel the vibrations of the noise), DIZZINESS (dizzy) and HEADACHE (Headache) outcome was unknown.            No concomitant medications reported. No treatment information was provided. Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was not applicable.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain upper, Fatigue, Pyrexia
Clinical narrative: Fever; Fatigue, laid down entire day; Stomach pain; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever), FATIGUE (Fatigue, laid down entire day) and ABDOMINAL PAIN UPPER (Stomach pain) in a 45-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038C21A and 005C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Jun-2021, the patient experienced PYREXIA (Fever), FATIGUE (Fatigue, laid down entire day) and ABDOMINAL PAIN UPPER (Stomach pain). At the time of the report, PYREXIA (Fever), FATIGUE (Fatigue, laid down entire day) and ABDOMINAL PAIN UPPER (Stomach pain) outcome was unknown.            No concomitant medications reported.  The patient had a lot of stomach pain. He had to go to bathroom couple of times. He also had fever and fatigue. He laid down entire day. No treatment information was provided. Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was not applicable.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Dizziness, Headache, Myalgia
Clinical narrative: Diagnosed with Covid After 1st shot; Weakness; dizziness; bodyache; headache; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Diagnosed with Covid After 1st shot), ASTHENIA (Weakness), DIZZINESS (dizziness), MYALGIA (bodyache) and HEADACHE (headache) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Jun-2021, the patient experienced ASTHENIA (Weakness), DIZZINESS (dizziness), MYALGIA (bodyache) and HEADACHE (headache). On 04-Jun-2021, the patient experienced COVID-19 (Diagnosed with Covid After 1st shot). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 1 dosage form and DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, EPHEDRINE SULFATE, ETHANOL, PARACETAMOL (NYQUIL) at a dose of 1 dosage form. At the time of the report, COVID-19 (Diagnosed with Covid After 1st shot), ASTHENIA (Weakness), DIZZINESS (dizziness), MYALGIA (bodyache) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-Jun-2021, SARS-CoV-2 test: positive (Positive) diagnosed with Covid after 1st shot.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 17-Jun-2021: Added lab data, treatment medication and patient anatomical section.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Diagnosed with Covid After 1st shot; Weakness; dizziness; bodyache; headache; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Diagnosed with Covid After 1st shot), ASTHENIA (Weakness), DIZZINESS (dizziness), MYALGIA (bodyache) and HEADACHE (headache) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Jun-2021, the patient experienced ASTHENIA (Weakness), DIZZINESS (dizziness), MYALGIA (bodyache) and HEADACHE (headache). On 04-Jun-2021, the patient experienced COVID-19 (Diagnosed with Covid After 1st shot). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 1 dosage form and DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, EPHEDRINE SULFATE, ETHANOL, PARACETAMOL (NYQUIL) at a dose of 1 dosage form. At the time of the report, COVID-19 (Diagnosed with Covid After 1st shot), ASTHENIA (Weakness), DIZZINESS (dizziness), MYALGIA (bodyache) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-Jun-2021, SARS-CoV-2 test: positive (Positive) diagnosed with Covid after 1st shot.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 17-Jun-2021: Added lab data, treatment medication and patient anatomical section.
Sex: M
Vaccine: COVID19
Symptoms: Extra dose administered
Clinical narrative: Received 3 doses of Moderna vaccine; This spontaneous case was reported by a consumer and describes the occurrence of EXTRA DOSE ADMINISTERED (Received 3 doses of Moderna vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced EXTRA DOSE ADMINISTERED (Received 3 doses of Moderna vaccine). At the time of the report, EXTRA DOSE ADMINISTERED (Received 3 doses of Moderna vaccine) had resolved.            No Concomitant medications were provided No Treatment information provided
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain in extremity, Rash, Urticaria
Clinical narrative: Hives on lips, face, chest, head, arms, throat; Pain in arm so much that if arm moves; Rash on stomach, back, chest; Feels like throwing up.; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives on lips, face, chest, head, arms, throat), PAIN IN EXTREMITY (Pain in arm so much that if arm moves), RASH (Rash on stomach, back, chest) and NAUSEA (Feels like throwing up.) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 005C21A and 038C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced URTICARIA (Hives on lips, face, chest, head, arms, throat), PAIN IN EXTREMITY (Pain in arm so much that if arm moves), RASH (Rash on stomach, back, chest) and NAUSEA (Feels like throwing up.). At the time of the report, URTICARIA (Hives on lips, face, chest, head, arms, throat), PAIN IN EXTREMITY (Pain in arm so much that if arm moves), RASH (Rash on stomach, back, chest) and NAUSEA (Feels like throwing up.) outcome was unknown.            Relevant concomitant medications were not provided.  Treatment medication was not provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Pneumonitis
Clinical narrative: Develop an inflammatory lung disease; This spontaneous case was reported by a physician and describes the occurrence of PNEUMONITIS (Develop an inflammatory lung disease) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001C21A and 008C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ATORVASTATIN and SILDENAFIL CITRATE (VIAGRA) for an unknown indication.   On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PNEUMONITIS (Develop an inflammatory lung disease). At the time of the report, PNEUMONITIS (Develop an inflammatory lung disease) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient had a costophrenic chest x-ray on 19-May-2021, he has multiple 5 cm cavities, he only have inflammatory labs, no malignancy or infections.  Treatment information was not provided.   This case was linked to MOD-2021-215987 (Patient Link).
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Parosmia
Clinical narrative: weird smell that would come and go/ thought it was propane gas/ weird gross smell, stinky; This spontaneous case was reported by a consumer and describes the occurrence of PAROSMIA (weird smell that would come and go/ thought it was propane gas/ weird gross smell, stinky) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003A21A) for COVID-19 vaccination.     The patient's past medical history included Joint reconstruction (shoulder reconstruction). Concurrent medical conditions included Breast cancer. Concomitant products included ANASTROZOLE for Breast cancer, LEVOTHYROXINE, CLONAZEPAM (CLONOPIN), AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL), ARIPIPRAZOLE (ABILIFY), METOPROLOL, VITAMIN D3, CALCIUM and MONASCUS PURPUREUS (RED YEAST RICE) for an unknown indication.   On 24-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced PAROSMIA (weird smell that would come and go/ thought it was propane gas/ weird gross smell, stinky). At the time of the report, PAROSMIA (weird smell that would come and go/ thought it was propane gas/ weird gross smell, stinky) had resolved.            It was reported that, the smell did not last very long when it came. It went away sometime between 15-May-2021 to 02-Jun-2021.  Treatment information not provided.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Fatigue, Illness, Nasal congestion, Sinusitis
Clinical narrative: Got sick 5 days after the 1st dose; Coughing after the 1st dose; Sneezing after the 1st dose; Congestion after the 1st dose; Secondary sinus infection after the 1st dose; Fatigue after the 1st dose/very tired fatigue; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Got sick 5 days after the 1st dose), COUGH (Coughing after the 1st dose), SNEEZING (Sneezing after the 1st dose), NASAL CONGESTION (Congestion after the 1st dose) and SINUSITIS (Secondary sinus infection after the 1st dose) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sinus infection. Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), PROGESTERONE and ESTRADIOL (DIVIGEL) for an unknown indication.    On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced ILLNESS (Got sick 5 days after the 1st dose), COUGH (Coughing after the 1st dose), SNEEZING (Sneezing after the 1st dose), NASAL CONGESTION (Congestion after the 1st dose), SINUSITIS (Secondary sinus infection after the 1st dose) and FATIGUE (Fatigue after the 1st dose/very tired fatigue). The patient was treated with FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]) for Nasal congestion, at a dose of UNK nasal spray; AZELASTINE HYDROCHLORIDE (ASTELIN [AZELASTINE HYDROCHLORIDE]) for Nasal congestion, at a dose of UNK nasal spray; CEPHALEXIN [CEFALEXIN] at an unspecified dose and frequency and CIPROFLOXACIN for Infection, at a dose of 500 mg twice a day. At the time of the report, ILLNESS (Got sick 5 days after the 1st dose), COUGH (Coughing after the 1st dose), SNEEZING (Sneezing after the 1st dose), NASAL CONGESTION (Congestion after the 1st dose), SINUSITIS (Secondary sinus infection after the 1st dose) and FATIGUE (Fatigue after the 1st dose/very tired fatigue) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       On an unknown date, the patient visited an ENT as her symptoms were worsening. The ENT diagnosed the patient with a secondary sinus infection which they state was not related to COVID-19. On an unknown date, it was reported that the patient discontinued cephalexin after 4 days due to culture insensitivity.   Most recent FOLLOW-UP information incorporated above includes: On 11-Jun-2021: Follow-up received and reporter information and patient demographics updated, vaccine information, and concomitant/treatment medication information updated, event terms and onset updated and outcome updated to recovered/resolved.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Sneezing
Clinical narrative: Got sick 5 days after the 1st dose; Coughing after the 1st dose; Sneezing after the 1st dose; Congestion after the 1st dose; Secondary sinus infection after the 1st dose; Fatigue after the 1st dose/very tired fatigue; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Got sick 5 days after the 1st dose), COUGH (Coughing after the 1st dose), SNEEZING (Sneezing after the 1st dose), NASAL CONGESTION (Congestion after the 1st dose) and SINUSITIS (Secondary sinus infection after the 1st dose) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sinus infection. Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), PROGESTERONE and ESTRADIOL (DIVIGEL) for an unknown indication.    On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced ILLNESS (Got sick 5 days after the 1st dose), COUGH (Coughing after the 1st dose), SNEEZING (Sneezing after the 1st dose), NASAL CONGESTION (Congestion after the 1st dose), SINUSITIS (Secondary sinus infection after the 1st dose) and FATIGUE (Fatigue after the 1st dose/very tired fatigue). The patient was treated with FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]) for Nasal congestion, at a dose of UNK nasal spray; AZELASTINE HYDROCHLORIDE (ASTELIN [AZELASTINE HYDROCHLORIDE]) for Nasal congestion, at a dose of UNK nasal spray; CEPHALEXIN [CEFALEXIN] at an unspecified dose and frequency and CIPROFLOXACIN for Infection, at a dose of 500 mg twice a day. At the time of the report, ILLNESS (Got sick 5 days after the 1st dose), COUGH (Coughing after the 1st dose), SNEEZING (Sneezing after the 1st dose), NASAL CONGESTION (Congestion after the 1st dose), SINUSITIS (Secondary sinus infection after the 1st dose) and FATIGUE (Fatigue after the 1st dose/very tired fatigue) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       On an unknown date, the patient visited an ENT as her symptoms were worsening. The ENT diagnosed the patient with a secondary sinus infection which they state was not related to COVID-19. On an unknown date, it was reported that the patient discontinued cephalexin after 4 days due to culture insensitivity.   Most recent FOLLOW-UP information incorporated above includes: On 11-Jun-2021: Follow-up received and reporter information and patient demographics updated, vaccine information, and concomitant/treatment medication information updated, event terms and onset updated and outcome updated to recovered/resolved.
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: got my second shot 3 weeks after the first dose; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got my second shot 3 weeks after the first dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got my second shot 3 weeks after the first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got my second shot 3 weeks after the first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. No treatment details were provided.   Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of dizziness (dizzy/lightheaded) in a patient, of an unknown age and gender, who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. On an unknown date, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced dizziness (dizzy/lightheaded). The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown.
Sex: U
Vaccine: COVID19
Symptoms: Diarrhoea, Myalgia
Clinical narrative: diarrhea; a little soreness on my arm; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea) and MYALGIA (a little soreness on my arm) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIARRHOEA (diarrhea) and MYALGIA (a little soreness on my arm). At the time of the report, DIARRHOEA (diarrhea) and MYALGIA (a little soreness on my arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information given. No treatment information provided.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: Follow up received contains no new information.
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: It has been 45 days since the patient's first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (It has been 45 days since the patient's first dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 074A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (It has been 45 days since the patient's first dose). On 10-Jun-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (It has been 45 days since the patient's first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided.  No treatment information provided.   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: No newinformation.
Sex: U
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Missed second dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed second dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed second dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed second dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported. Treatment medication was not provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: Tingling in the Left Arm and Left Shoulder (Injected Arm); This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (Tingling in the Left Arm and Left Shoulder (Injected Arm)) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 054C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-May-2021, the patient experienced PARAESTHESIA (Tingling in the Left Arm and Left Shoulder (Injected Arm)). At the time of the report, PARAESTHESIA (Tingling in the Left Arm and Left Shoulder (Injected Arm)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  No treatment information was provided.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Vaccine dose was administered from the vial punctured for > 12 hours; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine dose was administered from the vial punctured for > 12 hours) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine dose was administered from the vial punctured for > 12 hours). On 09-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine dose was administered from the vial punctured for > 12 hours) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: pain at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (pain at the injection site) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (pain at the injection site). At the time of the report, VACCINATION SITE PAIN (pain at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       treatment information not provided. Concomitant medications were not provided.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: Numbness in little finger of arm of injection after 2nd dose; Tingling in little finger of arm of injection after 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Numbness in little finger of arm of injection after 2nd dose) and PARAESTHESIA (Tingling in little finger of arm of injection after 2nd dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 24-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (Numbness in little finger of arm of injection after 2nd dose) and PARAESTHESIA (Tingling in little finger of arm of injection after 2nd dose). At the time of the report, HYPOAESTHESIA (Numbness in little finger of arm of injection after 2nd dose) had not resolved and PARAESTHESIA (Tingling in little finger of arm of injection after 2nd dose) outcome was unknown.            No concomitant medications reported. Treatment information not provided.
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Pain
Clinical narrative: Full body aches; Pain in opposite shoulder of injection; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Full body aches) and ARTHRALGIA (Pain in opposite shoulder of injection) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Thyroid disorder.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN (Full body aches) and ARTHRALGIA (Pain in opposite shoulder of injection). At the time of the report, PAIN (Full body aches) and ARTHRALGIA (Pain in opposite shoulder of injection) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant products included thyroid medication daily.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jul-2021: Follow-up received on 31-jul-2021 contains updated event outcome of both the events from Unknown to Resolved.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Vaccine dose was administered from the vial punctured for > 12 hours; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine dose was administered from the vial punctured for > 12 hours) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine dose was administered from the vial punctured for > 12 hours). On 09-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine dose was administered from the vial punctured for > 12 hours) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were provided by the reporter.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Rash erythematous, Rash pruritic
Clinical narrative: Reddish,itching rash on legs; Itching rash on legs; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (Reddish,itching rash on legs) and RASH PRURITIC (Itching rash on legs) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037 and 040B21A) for COVID-19 vaccination.     No medical history was reported.  Concomitant products included AMLODIPINE, FOLIC ACID and MONTELUKAST for an unknown indication.   On 30-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Jun-2021, the patient experienced RASH ERYTHEMATOUS (Reddish,itching rash on legs) and RASH PRURITIC (Itching rash on legs). The patient was treated with CORTISONE on 10-Jun-2021 for Itchy rash, at a dose of UNK dosage form. At the time of the report, RASH ERYTHEMATOUS (Reddish,itching rash on legs) and RASH PRURITIC (Itching rash on legs) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: side effect; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (side effect) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (side effect). At the time of the report, VACCINATION COMPLICATION (side effect) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Relevant concomitant medications was reported.  Treatment information was not provided
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site mass
Clinical narrative: alump appeared in the injection site; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE MASS (alump appeared in the injection site) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Jun-2021, the patient experienced VACCINATION SITE MASS (alump appeared in the injection site). At the time of the report, VACCINATION SITE MASS (alump appeared in the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medication were reported.  No Treatment information was reported.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Eating disorder, Feeling abnormal, Headache, Mouth swelling, Myalgia
Clinical narrative: difficult to eat; had a reaction to the second dose; sore throat; roof of mouth sore; roof of mouth swollen; roof of mouth red; night sweats; didn't feel good; headache; feverish; sore left upper arm / sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (sore left upper arm / sore arm), NIGHT SWEATS (night sweats), FEELING ABNORMAL (didn't feel good), OROPHARYNGEAL PAIN (sore throat) and ORAL PAIN (roof of mouth sore) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, the patient experienced MYALGIA (sore left upper arm / sore arm). On 03-Jun-2021, the patient experienced NIGHT SWEATS (night sweats), FEELING ABNORMAL (didn't feel good), HEADACHE (headache) and PYREXIA (feverish). On 05-Jun-2021, the patient experienced OROPHARYNGEAL PAIN (sore throat), ORAL PAIN (roof of mouth sore), MOUTH SWELLING (roof of mouth swollen) and ORAL MUCOSAL ERYTHEMA (roof of mouth red). On an unknown date, the patient experienced EATING DISORDER (difficult to eat) and VACCINATION COMPLICATION (had a reaction to the second dose). On 09-May-2021, MYALGIA (sore left upper arm / sore arm) had resolved. On 04-Jun-2021, NIGHT SWEATS (night sweats) had resolved. At the time of the report, FEELING ABNORMAL (didn't feel good), OROPHARYNGEAL PAIN (sore throat), ORAL PAIN (roof of mouth sore), MOUTH SWELLING (roof of mouth swollen), HEADACHE (headache), PYREXIA (feverish), ORAL MUCOSAL ERYTHEMA (roof of mouth red), EATING DISORDER (difficult to eat) and VACCINATION COMPLICATION (had a reaction to the second dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant products reported  No treatment products reported
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Night sweats, Oral mucosal erythema, Oral pain, Oropharyngeal pain, Pyrexia
Clinical narrative: difficult to eat; had a reaction to the second dose; sore throat; roof of mouth sore; roof of mouth swollen; roof of mouth red; night sweats; didn't feel good; headache; feverish; sore left upper arm / sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (sore left upper arm / sore arm), NIGHT SWEATS (night sweats), FEELING ABNORMAL (didn't feel good), OROPHARYNGEAL PAIN (sore throat) and ORAL PAIN (roof of mouth sore) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, the patient experienced MYALGIA (sore left upper arm / sore arm). On 03-Jun-2021, the patient experienced NIGHT SWEATS (night sweats), FEELING ABNORMAL (didn't feel good), HEADACHE (headache) and PYREXIA (feverish). On 05-Jun-2021, the patient experienced OROPHARYNGEAL PAIN (sore throat), ORAL PAIN (roof of mouth sore), MOUTH SWELLING (roof of mouth swollen) and ORAL MUCOSAL ERYTHEMA (roof of mouth red). On an unknown date, the patient experienced EATING DISORDER (difficult to eat) and VACCINATION COMPLICATION (had a reaction to the second dose). On 09-May-2021, MYALGIA (sore left upper arm / sore arm) had resolved. On 04-Jun-2021, NIGHT SWEATS (night sweats) had resolved. At the time of the report, FEELING ABNORMAL (didn't feel good), OROPHARYNGEAL PAIN (sore throat), ORAL PAIN (roof of mouth sore), MOUTH SWELLING (roof of mouth swollen), HEADACHE (headache), PYREXIA (feverish), ORAL MUCOSAL ERYTHEMA (roof of mouth red), EATING DISORDER (difficult to eat) and VACCINATION COMPLICATION (had a reaction to the second dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant products reported  No treatment products reported
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: difficult to eat; had a reaction to the second dose; sore throat; roof of mouth sore; roof of mouth swollen; roof of mouth red; night sweats; didn't feel good; headache; feverish; sore left upper arm / sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (sore left upper arm / sore arm), NIGHT SWEATS (night sweats), FEELING ABNORMAL (didn't feel good), OROPHARYNGEAL PAIN (sore throat) and ORAL PAIN (roof of mouth sore) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, the patient experienced MYALGIA (sore left upper arm / sore arm). On 03-Jun-2021, the patient experienced NIGHT SWEATS (night sweats), FEELING ABNORMAL (didn't feel good), HEADACHE (headache) and PYREXIA (feverish). On 05-Jun-2021, the patient experienced OROPHARYNGEAL PAIN (sore throat), ORAL PAIN (roof of mouth sore), MOUTH SWELLING (roof of mouth swollen) and ORAL MUCOSAL ERYTHEMA (roof of mouth red). On an unknown date, the patient experienced EATING DISORDER (difficult to eat) and VACCINATION COMPLICATION (had a reaction to the second dose). On 09-May-2021, MYALGIA (sore left upper arm / sore arm) had resolved. On 04-Jun-2021, NIGHT SWEATS (night sweats) had resolved. At the time of the report, FEELING ABNORMAL (didn't feel good), OROPHARYNGEAL PAIN (sore throat), ORAL PAIN (roof of mouth sore), MOUTH SWELLING (roof of mouth swollen), HEADACHE (headache), PYREXIA (feverish), ORAL MUCOSAL ERYTHEMA (roof of mouth red), EATING DISORDER (difficult to eat) and VACCINATION COMPLICATION (had a reaction to the second dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant products reported  No treatment products reported
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Facial pain, Swelling face, Tenderness
Clinical narrative: Her face started to feel sore/her face, is very sore, tender, and swollen; Her face, is very sore, tender, and swollen; Face is tender; This spontaneous case was reported by a consumer and describes the occurrence of FACIAL PAIN (Her face started to feel sore/her face, is very sore, tender, and swollen), SWELLING FACE (Her face, is very sore, tender, and swollen) and TENDERNESS (Face is tender) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ESCITALOPRAM OXALATE (LEXAPRO), SPIRONOLACTONE, MINOXIDIL and ETHINYLESTRADIOL, LEVONORGESTREL (LEVORA [ETHINYLESTRADIOL;LEVONORGESTREL]) for an unknown indication.   On 08-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Jun-2021, the patient experienced FACIAL PAIN (Her face started to feel sore/her face, is very sore, tender, and swollen), SWELLING FACE (Her face, is very sore, tender, and swollen) and TENDERNESS (Face is tender). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, FACIAL PAIN (Her face started to feel sore/her face, is very sore, tender, and swollen), SWELLING FACE (Her face, is very sore, tender, and swollen) and TENDERNESS (Face is tender) outcome was unknown.            The patient symptom included the patient had symptom where a filler in the face, also had face tender.